Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/219441
Title: | Sex differences in prolactin levels and clinical outcomes in patients with a first psychotic episode |
Author: | Jordà Baleri, Teresa Garriga, Marina Mezquida Mateos, Gisela Cuesta, Manuel J. Martínez-Arán, Anabel, 1971- García Rizo, Clemente Lobo, Antonio González-Pinto, Ana Díaz Caneja, Covadonga M. Roldán, Alexandra Vieta i Pascual, Eduard, 1963- Baeza, Inmaculada, 1970- Trabsa, Amira Montalvo, Itziar Tortorella, Alfonso Menculini, Giulia Verdolini, Norma Ramos Quiroga, Josep Antoni Sánchez Torres, Ana M. Bernardo Arroyo, Miquel Amoretti Guadall, Silvia PEPs Group |
Keywords: | Psicosi Prolactina Diferències entre sexes Símptomes Antipsicòtics Psychoses Prolactin Sex differences Symptoms Antipsychotic drugs |
Issue Date: | Nov-2024 |
Publisher: | Elsevier Ltd. |
Abstract: | Aim: To analyze the clinical, neurocognitive, and functional impact of prolactin levels according to sex in patients with a First Episode Psychosis (FEP). Methods: We measured prolactin levels in 221 non-affective FEP patients treated with antipsychotics (AP) and 224 healthy controls, at baseline and 2-year follow-up. We examined whether the relationships between clinical and functional variables were mediated by prolactin, controlling for antipsychotic use, according to sex. Results: Prolactin levels were higher in patients when compared to controls at both time points. Baseline factors associated with prolactin were chlorpromazine equivalents, attention, and executive functioning. In the FEP group, prolactin levels were associated with functioning and diminished expression in males, and with working memory in females. Prolactin levels (p=0.0134) played a role as a mediator between negative symptomatology (p=0.086) and functional outcome (p=0.008) only in FEP male patients at baseline. Conclusions: Prolactin plays a role in the functionality and clinical symptomatology of FEP patients. Our results suggest that pharmacological counselling in patients with hyperprolactinemia at baseline and negative symptomatology might improve their functional and clinical outcomes. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1016/j.psyneuen.2024.107112 |
It is part of: | Psychoneuroendocrinology, 2024, vol. 169 |
URI: | https://hdl.handle.net/2445/219441 |
Related resource: | https://doi.org/10.1016/j.psyneuen.2024.107112 |
ISSN: | 0306-4530 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut de Neurociències (UBNeuro)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
874351.pdf | 2.09 MB | Adobe PDF | View/Open Request a copy |
Document embargat fins el
31-10-2025
This item is licensed under a
Creative Commons License